Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of CKD-348(3) vs Coadministered Components in Healthy Volunteers
NCT05192356Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2022
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan, Levamlodipine, rosuvastatin and ezetimibe in hypertension (HTN) and dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-Time Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started Feb 2022; status: completed.
02
Drugs
telmisartanLevamlodipinerosuvastatinezetimibe
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT05192356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192356.